BarbaraJGitlitzMD

Oncology • Los Angeles, CA

Associate Clinical Professor of Medicine, USC-Keck School of Medicine

Join to view full profile

Dr. Gitlitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gitlitz's full profile

Already have an account?

Office
1441 Eastlake Ave
Nor 8302e
Los Angeles, CA 90089
Phone+1 323-865-3105

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1990 - 1992
UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1989 - 1990
Stony Brook University Health Sciences Center School of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 1990 - 2026

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Vaccine Therapy in Treating Patients With Advanced Kidney Cancer Start of enrollment: 1997 Jun 01
Completed
Phase 1
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2004 Sep 01
Terminated
Phase 2
Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer Start of enrollment: 2006 Apr 01
Withdrawn
Phase 1, Phase 2
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2006 Nov 01
Completed
Phase 2
A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma Start of enrollment: 2008 Apr 01
Withdrawn
Phase 1, Phase 2
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network Start of enrollment: 2010 Nov 01
Terminated
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2012 Jul 24
Completed
Phase 1
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2013 May 01
Terminated
Phase 2
Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide Start of enrollment: 2014 Aug 22
Withdrawn
Join now to see all

Publications & Presentations

PubMed

Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
Alexandra Jackovich, Barbara J Gitlitz, Justin Wayne Wong Tiu-Lim, Vinay Duddalwar, Kevin George King
Oncotarget. 2024-07-10
10 citations
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer.
Barbara J. Gitlitz, Silvia Novello, Tiziana Vavalà, Marisa A. Bittoni, Alicia Sable-Hunt
JTO Clinical and Research Reports. 2021-07-01
17 citations
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Dise...
Karen L. Reckamp, Paul Frankel, Nora Ruel, Philip C. Mack, Barbara J. Gitlitz
Frontiers in Oncology. 2019-03-11

Journal Articles

Transcribed Ultraconserved Region 339 Promotes Carcinogenesis by Modulating Tumor Suppressor microRNAs
Barbara Gitlitz, MD, Nature

Press Mentions

New Study Seeks Origins of Young Lung CancerFebruary 23rd, 2021
Distinct Genomic Differences Evident in Younger Patients with Lung CancerFebruary 5th, 2016
Lung Cancer Research Shows Distinct Genomic Differences in Younger PatientsJanuary 6th, 2016
Join now to see all